Centessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest Update

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 3,630,000 shares, a growth of 8.4% from the November 30th total of 3,350,000 shares. Based on an average daily volume of 539,100 shares, the days-to-cover ratio is currently 6.7 days. Approximately 4.0% of the shares of the company are sold short.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 11,742 shares of Centessa Pharmaceuticals stock in a transaction on Friday, October 25th. The stock was sold at an average price of $15.38, for a total transaction of $180,591.96. Following the completion of the sale, the insider now owns 183,266 shares of the company’s stock, valued at approximately $2,818,631.08. This trade represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 22,205 shares of Centessa Pharmaceuticals stock in a transaction on Monday, October 21st. The stock was sold at an average price of $15.80, for a total value of $350,839.00. Following the sale, the chief executive officer now directly owns 663,456 shares of the company’s stock, valued at $10,482,604.80. This represents a 3.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 368,023 shares of company stock valued at $6,335,574 in the last quarter. 11.59% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Centessa Pharmaceuticals by 103.1% during the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after purchasing an additional 1,509 shares during the last quarter. Quarry LP grew its holdings in shares of Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after purchasing an additional 3,108 shares during the last quarter. Sandia Investment Management LP bought a new stake in shares of Centessa Pharmaceuticals during the second quarter worth about $90,000. Finally, Fred Alger Management LLC bought a new stake in shares of Centessa Pharmaceuticals during the second quarter worth about $99,000. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Performance

Centessa Pharmaceuticals stock opened at $16.75 on Thursday. Centessa Pharmaceuticals has a 12-month low of $6.65 and a 12-month high of $18.97. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The business’s 50-day moving average price is $16.80 and its two-hundred day moving average price is $14.03. The stock has a market cap of $2.21 billion, a PE ratio of -10.95 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. As a group, analysts expect that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on CNTA shares. B. Riley initiated coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 target price for the company. Guggenheim raised their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Jefferies Financial Group raised their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, BMO Capital Markets raised their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research report on Monday, September 16th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.